Blueprint to defeat dementia in 5 years
•Download as PPTX, PDF•
2 likes•688 views
Dr Matthew Norton outlines a blueprint to defeat dementia through increased research funding and international collaboration. Key points include: 1) Alzheimer's Research UK has helped advance understanding of dementia through discoveries like 21 of the 22 known Alzheimer's risk genes and dangers of antipsychotic overprescription. 2) A £100 million, 5-year research strategy aims to develop treatments that can slow or stop the disease by understanding its causes, finding drug targets, and testing in appropriate populations. 3) International partnerships through the G8 Dementia Summit and World Dementia Council seek to find a cure or disease-modifying therapy by 2025 through greater funding and reducing regulatory barriers to innovation.
Recommended
More Related Content
Similar to Blueprint to defeat dementia in 5 years
Similar to Blueprint to defeat dementia in 5 years (20)
More from Alexis May
More from Alexis May (20)
Recently uploaded
Recently uploaded (20)
Blueprint to defeat dementia in 5 years
- 1. A blueprint to defeat dementia Dr Matthew Norton, Head of Policy and Public Affairs
- 4. How do we defeat dementia? Causes Diagnosis Prevention Treatments
- 5. Our progress to date • Helped shape the current understanding of dementia: our funding underpinning the discovery of 21 of the 22 known Alzheimer’s risk genes • Our investigation into the dangers of antipsychotic drug over-prescription saved countless lives • Our funding is allowing Prof Rick Livesey at University of Cambridge develop a technique to turn skin cells from patients into functioning nerve cells in the lab. These cells recreate many of the fundamental features of Alzheimer’s in a matter of days rather than decades. Over the past year, his research has been transforming how we study Alzheimer’s in the lab and providing new and efficient screening methods for new drugs
- 6. Development of new treatments • Current treatments help with symptoms Donepezil, rivastigmine, galantamine, memantine There are no treatments that can slow or stop the disease process To develop such treatments, we must • UNDERSTAND the disease • find suitable TARGETS for treatments • test the treatment in the right PEOPLE at the right TIME
- 7. Defeat Dementia £100 million, 5 years, a blueprint to defeat dementia
- 8. ARUK research strategy: 2014 Basic research into disease mechanisms Targeted research into critical disease mechanisms Clinical research to find better ways to assess and diagnose dementia diseases New potential targets for drugs New ways to assess drug effects on disease 1946 Cohort Longitudinal study of AD to define disease trajectory and identify subjects suitable for entering trials for new and existing drugs Clinical proof on concept study in selected populations Effective drugs for Alzheimer’s disease and other dementias – right drug, right patient, right time. Investigational drugs ARUK Dementia Consortium. ARUK Drug Discovery Institute ARUK Stem Cell Institute Crack-it Untangle New potential targets for drugs – world wide ARUK funding
- 11. Innovation in research ARUK Drug Discovery Institute
- 13. G8 Dementia Summit, December 2013 The G8 countries announced: • Identify a cure or a disease-modifying therapy for dementia by 2025 and to increase collectively and significantly the amount of funding for dementia research to reach that goal. • Appoint a global Dementia Innovation Envoy UK legacy event, June 2014 The UK-led event will focus on the execution timeline and plan towards a Global Dementia Innovation Fund to: • stimulate greater social impact investment and innovation in dementia research • improve the prevention and treatment of dementia • improve quality of life for people with dementia and their carers
- 14. World Dementia Council Chaired by Dementia Innovation Envoy, Dr Dennis Gillings ‘The council aims to stimulate innovation, development and commercialisation of life enhancing drugs, treatments and care for people with dementia, or at risk of dementia, within a generation. It will provide independent, non-governmental advocacy and global leadership. The views expressed by the council will be independent of any government and not representative of government policy.’ Key functions will be co-ordination and investment • Regulatory barriers • Revise investment incentives • Develop use of big data
- 15. The difference we can make
- 16. Delaying onset for 5 years: The impact for people with dementia
- 17. Delaying onset for 5 years : cost to UK economy
- 18. Slowing progression: the impact for people with dementia
Editor's Notes
- Why are we here? There are 820,000 people in the UK with dementia today – a number forecast to rise as the population ages. 25 million people, or a 1/2 of the UK’s population know someone with dementia. As well as the huge personal costs, dementia costs the UK economy 23billion a year, which is more than the cost of heart disease and stroke combined. Despite this, dementia research remains drastically underfunded, especially when compared to other major diseases. We’re here to find new treatments or preventions that can improve quality of life for everyone affected by dementia. The Queen’s Birthday Telegrams: in 1962: 200 telegrams in 2007: 8,439 telegrams 8x more spent on cancer research than dementia
- So how do we defeat dementia? We know now that dementia is the result of a complex set of brain diseases – so what progress do we need to make to defeat it? At Alzheimer’s Research UK, we believe the best way to beat dementia is by understanding it – we need to understand what causes dementia, what changes happen in the brain and why. We already know that the brain is v complex and dementia can be caused by a number of different underlying diseases. Only by understanding the detail of what is happening in the brain will scientists be able to develop better and more accurate ways of diagnosing dementia, give people a better understanding of the steps they could take to prevent or lower their risk of developing it, and to design new and effective treatments to tackle it. We are currently funding research into all of these areas.
- Current treatments help with symptoms – trap finger paracetamol. -Donepezil (Aricept), rivastigmine, galantamine, memantine. Boost chemicals help nerve cells communicate – dont stop disease progressing. This is a major goal of research. But not only do we need to understand the diseases to find suitable targets, but we need to test these potential new treatments in the right people at the right time. But low investment Cancer reaping rewards now from early stage investment
- We launched the Dementia Consortium – an innovative partnership between us and MRC Technology, Eisai and Lilly. The Consortium aims to expedite the development of new drugs for dementia by providing funding and expertise in support of research into new targets for dementia drug discovery. We had kick off meetings in the New Year, so the Consortium is open for business for teams in the UK and internationally. There is a rolling application process, with packs available from the Consortium website now. Late in 2013, we launched our plan to fund a dedicated drug discovery institute based at a leading institution here in the UK. We’ve been delighted at the expressions of interest we’ve received, and the review panel is currently undertaking the difficult task of determining which applicants go through to the next round. We’re incredibly excited about this development at the charity which, together with the Dementia Consortium, is providing a comprehensive approach to dementia drug discovery. It’s also inspiring our donors too, and right it should. Our grant scheme continues to fund the very best ideas in dementia research from fundamental discovery through to clinical application. Our 15 schemes mean we can continue to be a flexible and responsive funder, and last year we funded nearly 50 new projects. Together with the Institute and the Consortium, we are also looking at further strategic research opportunities where ARUK funding can catalyse a great deal more both within the UK and overseas. A couple of recent examples include our investment in the NC3Rs Crack It challenge to produce a human stem cell derived model for tau behaviour. We’ve also joined with Sage Bionetworks on a big data approach to identifying predictive biomarkers for cognitive decline. We’re supporting BIRAX – the Britain Israel Research and Academic Exchange Partnership – via the British Council – to fund new approaches in translational stem cell research for dementia. Finally, we’re working in partnership with NIHR DeNDRoN to deliver a new streamlined clinical research recruitment process. The scheme allows people affected by dementia and their families to sign up and provide data about themselves against which researchers can run feasibility checks for prospective studies. The scheme rolls out regionally in a month’s time, with a national launch later in the year which we hope will play a major part in reaching the Dementia Challenge’s 10% research involvement ambition for people with dementia.
- Appoint a global Dementia Innovation Envoy to draw together international expertise to stimulate innovation and to co-ordinate international efforts to attract new sources of finance, including exploring the possibility of developing a private and philanthropic fund to support global dementia innovation.